Vasoactive intestinal peptide (VIP) is a 28-amino acid peptide that belongs to a family of structurally related peptide hormones including pituitary adenylate cyclase-activating peptide (PACAP). These hormones are widely distributed in the nervous system, where they act as neurotransmitters. Their biological effects are mediated by specific receptors, VPAC1 and VPAC2, which have comparable affinity for VIP and PACAP, and PAC1, which binds VIP with 1,000-fold lower affinity than PACAP. Both peptides are involved in autonomic regulation of the cardiovascular system, where they exert positive inotropic and chronotropic effects, and cause coronary vasodilatation. Additionally, PACAP inhibits proliferation of cardiac fibroblasts. Several cardiovascular diseases, such as myocardial fibrosis, heart failure, cardiomyopathy and pulmonary hypertension, have been found to be associated with changes in myocardial VIP concentration or with alteration of affinity, density and physiological responsiveness of VIP/PACAP receptors. Application of the peptides or their agonists has beneficial effect in hypertension, heart failure and myocardial fibrosis. Taken together, VIP and PACAP have beneficial effects in various pathological conditions.
- MeSH
- hypofyzární adenylátcyklázu aktivující peptid metabolismus MeSH
- hypofyzární polypeptid aktivující adenylátcyklasu - receptory typu I metabolismus MeSH
- hypofyzární polypeptid aktivující adenylátcyklasu - receptory MeSH
- receptory vazoaktivního intestinálního peptidu typu I * metabolismus MeSH
- receptory vazoaktivního intestinálního peptidu typu II metabolismus MeSH
- vazoaktivní intestinální peptid * metabolismus MeSH
- Publikační typ
- časopisecké články MeSH
Vasoactive intestinal peptide (VIP) is a 28-amino acid peptide that belongs to a family of structurally related peptide hormones including pituitary adenylate cyclase-activating peptide (PACAP). These hormones are widely distributed in the nervous system, where they act as neurotransmitters. Their biological effects are mediated by specific receptors, VPAC1 and VPAC2, which have comparable affinity for VIP and PACAP, and PAC1, which binds VIP with 1,000-fold lower affinity than PACAP. Both peptides are involved in autonomic regulation of the cardiovascular system, where they exert positive inotropic and chronotropic effects, and cause coronary vasodilatation. Additionally, PACAP inhibits proliferation of cardiac fibroblasts. Several cardiovascular diseases, such as myocardial fibrosis, heart failure, cardiomyopathy and pulmonary hypertension, have been found to be associated with changes in myocardial VIP concentration or with alteration of affinity, density and physiological responsiveness of VIP/PACAP receptors. Application of the peptides or their agonists has beneficial effect in hypertension, heart failure and myocardial fibrosis. Taken together, VIP and PACAP have beneficial effects in various pathological conditions. (c) 2005 Prous Science. All rights reserved.
- MeSH
- autonomní nervový systém metabolismus MeSH
- cévy inervace metabolismus MeSH
- ganglia parasympatická metabolismus MeSH
- hypofyzární adenylátcyklázu aktivující peptid metabolismus MeSH
- hypofyzární polypeptid aktivující adenylátcyklasu - receptory typu I metabolismus MeSH
- kardiotonika terapeutické užití MeSH
- kardiovaskulární nemoci etiologie metabolismus prevence a kontrola MeSH
- kardiovaskulární systém inervace metabolismus MeSH
- lidé MeSH
- myokard metabolismus MeSH
- plicní hypertenze etiologie metabolismus prevence a kontrola MeSH
- receptory vazoaktivního intestinálního peptidu typu I metabolismus MeSH
- receptory vazoaktivního intestinálního peptidu typu II metabolismus MeSH
- signální transdukce MeSH
- srdeční selhání etiologie metabolismus prevence a kontrola MeSH
- vazoaktivní intestinální peptid metabolismus terapeutické užití MeSH
- vazodilatace účinky léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
